Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Market Closed - Canadian Securities Exchange Other stock markets 07:00:00 24/05/2024 pm IST			5-day change	1st Jan Change
1.6 ^CAD	0.00%		+11.89%	-24.53%

16/05	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
22/03	Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	13/02	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	30/12	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	15/23/15	CI
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/23/08	MT
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/23/08	MT
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101	08/23/08	CI
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/23/20	MT
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101	20/23/20	CI
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/23/20	MT
Bright Minds Biosciences Brief: Will Consolidate Its Common Shares On a 5) to 1 Basis; Co's post-Consolidation Shares Expected to Begin Trading on the CSE and The NASDAQ Capital Market on July 14, 2023	11/23/11	MT
Bright Minds Biosciences Announced Proposed Share Consolidation	22/23/22	MT
Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	16/23/16	CI
Bright Minds Biosciences Receives "Favorable" Written Opinion from International Searching Authority for BMB-202	19/23/19	MT
Bright Minds Biosciences Brief: Says Received a "Favorable" Written Opinion from International Searching Authority for BMB-202	19/23/19	MT
Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202	19/23/19	CI
Bright Minds Biosciences Provides Clinical Program Updates	27/23/27	MT
Bright Minds Biosciences Brief: Providing Clinical Program Updates and Outlines Anticipated Milestones for 2023	27/23/27	MT
Bright Minds Biosciences Inc. Provides Clinical Program Updates	27/23/27	CI
Bright Minds Biosciences Warned of Potential Nasdaq Delisting	09/23/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Highlights

Filters